
BMEA Stock Forecast & Price Target
BMEA Analyst Ratings
Bulls say
Biomea Fusion is poised for success with its focus on developing innovative treatments for diabetes and obesity, led by its promising lead asset icovamenib that targets the protein menin. With positive Phase 2b data expected in 2026 and a projected growing global market, the company has strong potential for success, yet there are risks involved in the development and commercialization process that should be considered by investors. In addition, the company's expansion plans into Europe could further increase its market reach and potential for growth.
Bears say
Biomea Fusion is a biotech company with a high risk profile due to its focus on earlier pipeline opportunities and limited commercialization potential in the highly competitive diabetes market. Additionally, the company has faced issues with its lead drug candidate, icovamenib, which has been placed on clinical hold by the FDA due to dose-related liver enzyme elevations. This, along with the potential for negative results in upcoming Phase 2 trials, could lead to significant setbacks for the company and hinder their attempts to address the growing need for innovative solutions for diabetes.
This aggregate rating is based on analysts' research of Biomea Fusion Inc and is not a guaranteed prediction by Public.com or investment advice.
BMEA Analyst Forecast & Price Prediction
Start investing in BMEA
Order type
Buy in
Order amount
Est. shares
0 shares